Search company, investor...
ConforMIS company logo

ConforMIS

conformis.com

Stage

IPO | IPO

Total Raised

$253.3M

Date of IPO

7/1/2015

Market Cap

0.02B

Stock Price

2.46

Revenue

$0000 

About ConforMIS

ConforMIS develops and commercializes medical devices for osteoarthritis treatment and joint damage. The company's intellectual property includes patents and patent applications in the areas of imaging software, image processing, implant design, surgical techniques, instrumentation, and manufacturing, spanning knee, hip, shoulder, spine, and small joints. ConforMIS knee implants and instrumentation are designed to address all stages of osteoarthritis, the most common reason for knee replacement surgery . All devices have been cleared by the US Food and Drug Administration for marketing in the US.

Headquarters Location

28 Crosby Drive

Bedford, Massachusetts, 01730,

United States

781-345-9001

Missing: ConforMIS's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: ConforMIS's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing ConforMIS

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

ConforMIS is included in 1 Expert Collection, including Medical Devices.

M

Medical Devices

3,501 items

https://www.advamed.org/membership-join/membership-directory/ - excludes those without working websites.

ConforMIS Patents

ConforMIS has filed 210 patents.

The 3 most popular patent topics include:

  • Orthopedic surgical procedures
  • Implants (medicine)
  • Prosthetics
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/22/2019

8/23/2022

Orthopedic surgical procedures, Surgery, Surgical instruments, Implants (medicine), Prosthetics

Grant

Application Date

10/22/2019

Grant Date

8/23/2022

Title

Related Topics

Orthopedic surgical procedures, Surgery, Surgical instruments, Implants (medicine), Prosthetics

Status

Grant

Latest ConforMIS News

FGlobal Hip Replacement Market Report 2023 - 2028: Featuring Smith & Nephew, Johnson & Johnson, Conformis and Integra lifesciences Among Others

Jan 23, 2023

The Global Hip Replacement Market will be around US$ 9 Billion by 2028 according to the publisher. Hip replacement is a surgical procedure to replace the hip joint entirely or partially with an artificial joint, called a prosthesis. It is a general surgery that is needed when the mobility of the hip joint is reduced, either due to damage or the hip joint has worn out. In addition, osteoarthritis, rheumatoid arthritis, osteonecrosis, fractures, and bone tumours usually require hip replacement surgery. According to World Health Organization (WHO), about 130 million people will suffer from osteoarthritis globally, and the disease will leave 40 million people disabled, by 2050. In 2021, the number of people suffering from osteoarthritis globally was 528 million. Global Hip Replacement Market will grow at a CAGR of 5.46% from 2023 to 2028 The increase in the geriatric population, increase in R&D activities for surgical procedures, product launch, and approval, growth in the number of patients undergoing hip replacement surgery, and increase in the government funds on healthcare, are some of the factors that aid the development of hip replacement market worldwide. However, high costs incurred on surgeries and R&D procedures, infrastructural limitations, and strict rules and regulations laid down by the government for new product approvals are expected to restrain the growth of the global hip replacement market. Product Segment Based on products, the global hip replacement market is segmented into; total hip replacement, partial hip replacement, and revision and hip resurfacing. Total hip replacement segments dominated the market share due to the growth in demand for minimally invasive surgeries and the technological advancements in the hip replacement market. Further, the rise in osteoarthritis cases will drive the segment's growth. The global hip replacement market was at US$ 6.54 Billion in 2022. End-user Segment The end-user segment is categorized into; hospitals and surgery centers, orthopedic clinics, and others. The hospitals and surgery category dominates in the end-user segment. The reason for this domination is the rise in hip replacement surgeries within these centers and facilities. In addition, they have the best available equipment and skilled health professionals, which also add to the segment's growth. The orthopedic clinic category is expected to grow at a lucrative rate over the forecast period. The growth of this category can be attributed to the increase in the number of orthopedic clinics, the availability of skilled health personnel, and well-developed infrastructure. Regional Insights The report classifies the region into; North America, Europe, Asia-Pacific, Latin America, Middle-East, and Africa. The rise in the patients with arthritis and the government's favorable reimbursement policies are expected to aid the dominance of the North American region. The Asia-Pacific region is anticipated to grow at an increasing rate over the forecast period. The region has a growing elderly population, which will increase the number of arthritis patients, and the government is actively providing funds for the healthcare sector. These factors will propel the growth of the market in the Asia-Pacific region. Key Market Players The global hip replacement market is very competitive and is filled with companies like; Smith & Nephew PLC, Johnson & Johnson, ConformisInc, Integra Lifesciences Corporation, MicroPort Scientific Corporation, Zimmer Biomet, Stryker, and Braun Melsungen AG. The players mentioned above are constantly involved in product innovation and development, technological betterment, and mergers and acquisitions to procure a higher market share. For instance, in August 2021, Zimmer Biomet announced that the company had been given the FDA 510k clearance of the ROSA Hip System for total hip replacement, which is robotically-assisted. Report Attribute

ConforMIS Frequently Asked Questions (FAQ)

  • Where is ConforMIS's headquarters?

    ConforMIS's headquarters is located at 28 Crosby Drive, Bedford.

  • What is ConforMIS's latest funding round?

    ConforMIS's latest funding round is IPO.

  • How much did ConforMIS raise?

    ConforMIS raised a total of $253.3M.

  • Who are the investors of ConforMIS?

    Investors of ConforMIS include AGC Equity Partners, Axel Johnson, MassDevelopment, Sovereign Fund of Kuwait, Aeris Capital and 6 more.

  • Who are ConforMIS's competitors?

    Competitors of ConforMIS include OrthAlign, ArthroSurface, Zipline Medical, Cord Blood Registry, Stanmore Implants, Fournitures Hospitalieres, Anteis, PEAK Surgical, Osteotech, NanoPowers and 18 more.

Compare ConforMIS to Competitors

F
Formae

Formae, Inc. Formae is developing new approaches to cartilage replacement for osteoarthritis, using hydrogels that closely mimic the mechanical properties of hyaline cartilage. Formae's approach is in that it is minimally invasive and aims to provide for total rather than focal joint resurfacing. The company has a broad portfolio of issued and pending patents and a well-defined product and regulatory strategy. The technology can be applied to any joint, and has the potential to be implanted arthroscopically. Following the completion of ex-vivo mechanical testing that will meet a critical regulatory milestone, Formae will be seeking funds to conduct in-vivo implantation and biocompatibility testing. .

OrthAlign Logo
OrthAlign

OrthAlign provides orthopedic surgeons with user-friendly and cost-effect technology for precise alignment.

D
Dynatherm Medical

DynaTherm Medical aims to develop and commercialize products for temperature management in surgical, emergency, field and industrial settings. The company's patent protected technology uses non-invasive negative pressure to access the body's natural thermoregulatory system, the AVA's (arteriovenous anastomoses).

A
Arbor Surgical Technologies

Arbor Surgical Technologies, Inc. with facilities located in Irvine and Portola Valley, CA (USA), is a privately held cardiovascular medical device company focused on the heart valve replacement market. Founded in 2002 by Dr. Thomas J. Fogarty and noted heart valve designer, Ernie Lane, Arbor is developing multiple technologies that have the potential to deliver significant clinical benefit to patients worldwide. Arbor intends to develop and commercialize its core technologies in varying combinations, giving the company the opportunity to create a broad portfolio of product offerings. Currently in clinical trials, Arbor is developing a tissue heart valve family of products designed for improved performance over existing valves and compatible implantation tools that simplify and speed valve replacement surgery. Arbor Surgical Technologies mission is to simplify cardiac valve surgery through the innovative development of a less invasive, unique implantation system and valves with superior performance and durability. Partnering with physicians, we will improve patient recovery by less invasive techniques and reduced surgery time. Ethical behavior with employees, surgeons, patients and suppliers is the keystone to our success.

A
Axis Surgical Technologies

Axis Surgical Technologies, Inc. aims to develop, manufacture, and market devices that improve quality and efficiency in spinal surgery, especially for minimally invasive surgical techniques. Based in Mountain View, California, Axis offers an integration of visualization and articulation capabilities and provides spinal surgery equipment. Axis' FDA Grant In March 2010, Axis announced that it received 510(k) clearance from the Food and Drug Administration to market its C-MOR„ Visualization Device to use in diagnostic and operative arthroscopic and endoscopic procedures. This portable tool provides visualization and illumination of an interior cavity through either a natural or surgical opening. The ergonomic lightweight device also offers practitioners the convenience of endoscopic visualization and efficient one-handed operating ability; this device can be employed in hospital outpatient departments, ambulatory surgery centers, and office surgery suites.

BioHorizons Logo
BioHorizons

BioHorizons is a provider in advanced dental implant technologies and tissue regeneration products in the dental implant industry. The company, based in Birmingham, Alabama, offers a broad spectrum of products for the replacement of missing teeth including dental implants, restorative and laboratory components, soft and hard tissue biologic products, and surgical planning software. BioHorizons' unique dental implant designs are recognized for intuitive design, excellent primary stability, and high-end, esthetic outcomes through the use of BioHorizons' Laser-Lok microchannel surface technology. Laser-Lok has been shown to uniquely achieve both bone and soft tissue attachment for long-term tissue maintenance. The company has six international subsidiaries and more than 50 distributors around the world.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.